Monte Rosa Therapeutics, Inc. GLUE

US Biotechnology

$10.71 ▲ +1.23% (+$0.13)

🔥 High Short Interest

Open $10.66

Prev Close $10.58

Day Range $10.40 – $10.86

52W Range $9.68 – $25.77

Market Cap $904.06M

Beta 1.36

EPS (TTM) $-1.74

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-06-24
Shares Out.	85,310,000
Website	monterosatx.com/ ↗
Phone	13026587581
Employees	173
Revenue	$54.4M
Gross Profit	$54.4M
Net Income	$3.1M
Free Cash Flow	-$174.4M
Total Assets	$697.7M
Total Liabilities	$201.5M
Equity	$496.2M

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Monte Rosa Therapeutics, Inc. is a publicly traded company under the ticker symbol GLUE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.